Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30258384 | 1.00 | RAB9A (0.64) | RAB9AALDH1A1KMT2APKMKDM4E | |
| SCHEMBL9861291 | 0.85 | HSD17B10 (0.71) | RAB9AALDH1A1KMT2AKDM4EHSD17B10 | |
| SCHEMBL28491071 | 0.83 | KMT2A (0.62) | ALDH1A1KMT2APKMKDM4EHPGD | |
| SCHEMBL2823735 | 0.83 | ALDH1A1 (0.68) | ALDH1A1KMT2APKMKDM4EHSD17B10 | |
| SCHEMBL28238437 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KMT2APKMKDM4EHPGD | |
| SCHEMBL11873963 | 0.82 | ALDH1A1 (0.55) | RAB9AALDH1A1KMT2APKMKDM4E | |
| SCHEMBL754748 | 0.82 | KMT2A (0.59) | ALDH1A1KMT2APKMKDM4EHPGD | |
| SCHEMBL19120252 | 0.81 | ALDH1A1 (0.54) | RAB9AALDH1A1KMT2APKMKDM4E | |
| SCHEMBL8624820 | 0.81 | RAB9A (0.63) | RAB9AALDH1A1KMT2APKMHSD17B10 | |
| SCHEMBL4452103 | 0.81 | ALDH1A1 (0.53) | RAB9AALDH1A1KMT2APKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947667-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| WO-2020198264-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2020-10-01 | — | — | WO | claimed |
| EP-2643340-B1 | COMPOSITIONS AND METHODS FOR FUNCTIONAL GLYCOMICS | UNIV EMORY (US) | 2019-07-31 | — | — | EP | claimed |
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-05-21 | — | — | US | claimed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| US-11788080-B2 | Modified cleavases, uses thereof and related kits | Encodia, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230257727-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | disclosed |
| EP-4127157-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20230021091-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11427814-B2 | Modified cleavases, uses thereof and related kits | Encodia, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-2643340-A2 | COMPOSITIONS AND METHODS FOR FUNCTIONAL GLYCOMICS | Emory University (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012071371-A2 | COMPOSITIONS AND METHODS FOR FUNCTIONAL GLYCOMICS | EMORY UNIVERSITY (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-05-21 | — | — | US | disclosed |
| EP-0633145-B1 | Thermal recording sheet | JUJO PAPER CO LTD (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5612279-A | REVERSIBILITY | NIPPON PAPER INDUSTRIES, LTD. (JP) | 1997-03-18 | — | — | US | disclosed |
| US-5470816-A | Urea developers | NIPPON PAPER INDUSTRIES CO., LTD. (JP) | 1995-11-28 | — | — | US | disclosed |
| EP-0633145-A1 | Thermal recording sheet | NIPPON PAPER INDUSTRIES CO., LTD. (JP) | 1995-01-11 | — | — | EP | disclosed |
| US-4537718-A | GLUTATHIONE JOINED BY LINKAGE GROUPS TO A SECTROSCOPIC REPORTER | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1985-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | CLIC1, ASIC1, CLIC4 | RAB9A 870/4885ALDH1A1 1179/4885KMT2A 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.